logo
  Join        Login             Stock Quote

Oculus Innovative Sciences (OCLS) To Create Subsidiary For Anti-Infective Drug Assets

 November 26, 2012 11:42 AM


(By Balaseshan) Oculus Innovative Sciences Inc. (NASDAQ: OCLS) said it has initiated the process to create a wholly owned subsidiary that will hold the commercial healthcare company's anti-infective drug assets.

The company recently announced, that based upon market research, there appeared to be a significant opportunity for a new drug utilizing the Microcyn Technology for surgical suite use.

The company's new surgical formulation has been finalized and the company is now preparing the clinical strategy in preparation for discussions with the FDA.

Oculus management believes that the creation of this subsidiary will provide focused resources for the drug development platform as well as financing opportunities specific to the subsidiary, or future spinoff.

[Related -Chart Says This Retailer's Comeback Isn't Finished]

The objective is to generate funding for the company's FDA clinical trials without issuing additional shares of the parent company.

"The creation of a subsidiary allows us to better leverage our drug opportunities, including Oculus' surgical anti-infective program. We plan on exploring all strategic alternatives to unlock the value of these assets, which we believe will lead to new drug applications for Microcyn Technology within the surgical suite," said Hoji Alimi, founder and CEO of Oculus.

The company said the new subsidiary could allow its existing shareholders to gain equity in both entities, and moving forward should attract both biotech investors focused on its drug programs as well as fundamental investors whose priority is the sales growth and profitability of its medical device products.

[Related -ETF Performance Review: Major Asset Classes | 19 Dec 2014]

OCLS is trading up 1.43% at $0.710 on Monday. The stock has been trading between $0.60 and $1.65 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.